Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.

Zhong J, Xiang D, Ma X

Open source

DOI
10.1155/2022/2309339
Published
2022
Container
BioMed research international
Publisher
Not recorded
Open access
yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1155/2022/2309339,
  title = {Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.},
  author = {Zhong J and Xiang D and Ma X},
  year = {2022},
  journal = {BioMed research international},
  doi = {10.1155/2022/2309339},
  url = {https://doi.org/10.1155/2022/2309339}
}

RIS

TY  - JOUR
TI  - Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.
AU  - Zhong J
AU  - Xiang D
AU  - Ma X
PY  - 2022
JO  - BioMed research international
DO  - 10.1155/2022/2309339
UR  - https://doi.org/10.1155/2022/2309339
ER  - 

APA

J, Z., D, X., & X, M. (2022). Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.. BioMed research international. https://doi.org/10.1155/2022/2309339

Source records